Product Description
For CNS disorders (Sourced from: https://www.idorsia.com/media/news-details?newsId=2338761)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04452006 |
ID-088-101 | P1 |
Terminated |
Healthy Volunteers |
2021-04-20 |
12% |
2021-07-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |